In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arrow Group APS

Division of Allergan PLC

Latest From Arrow Group APS

Actavis’ Transformative Dealmaking

A steady stream of M&A and licensing activity, starting with the buyout of Andrx in 2006, spurred Actavis’ a.k.a. Watson’s transformation into a global specialty pharma. This led the way to the 2012 merger with Actavis and now the proposed buyout of Forest, creating a new, global specialty and generics player.

BioPharmaceutical Strategy

Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

BioPharmaceutical United States

Watson’s Transformative Deal-Making

A steady stream of M&A and licensing activity, starting with the buyout of Andrx in 2006, spurred Watson’s transformation into a global specialty pharma. This led the way to the 2012 merger with Actavis and now the proposed buyout of Forest, creating a new, global specialty and generics player.

BioPharmaceutical Business Strategies

Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff

Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Arrow International Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Allergan PLC
  • Senior Management
  • Anthony Tabatznik, CEO
  • Contact Info
  • Arrow Group APS
    Phone: (45) 45 17 03 00
    Hovedgaden 41,2.Sal
    Horsholm, 2970
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register